Table I.
Characteristics of patients with psoriasis on biologic therapy
| Variable | All patients |
|---|---|
| Age, mean ± SD (range), y | 51.5 ± 14.0 (17-84) |
| Sex | |
| Male, % (n/N) | 71.7 (114/159) |
| Female, % (n/N) | 28.3 (45/159) |
| Biologic therapies | |
| Anti–TNF-α (adalimumab, etanercept, golimumab), % (n/N) | 33.3 (53/159) |
| Anti–IL-17 (secukinumab, ixekizumab, brodalumab), % (n/N) | 47.8 (76/159) |
| Anti–IL-12/-23 (ustekinumab, guselkumab), % (n/N) | 18.9 (30/159) |
| Contact with suspected/confirmed COVID-19 patient, % (n/N) | 15.7 (25/159) |
| Patients with positive COVID-19 nasal swab, % (n/N)∗ | 0.0 (0/159) |
| Suspected COVID-19 symptoms, % (n/N)† | 18.2 (29/159) |
| Mild | 15.7 (25/159) |
| Moderate | 1.9 (3/159) |
| Severe | 0.6 (1/159) |
| Patients who had drug suspended, % (n/N) | 5.6 (9/159) |
IL, Interleukin; TNF, tumor necrosis factor.
∗
In March 2020 almost only hospitalized patients were tested with COVID-19 nasal swab (n = 0/1 positive nasal swab/hospitalized patients)
†
Suspected COVID-19 symptoms defined as: Mild: flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in ≤7 days without hospitalization. Moderate: flu-like symptoms, cough, low-grade fever, anosmia/ageusia, resolved in 8-16 days without hospitalization. Severe: serious symptoms that required hospitalization; 1 patient reported serious symptoms that required hospitalization (pneumococcal pneumonia with negative COVID-19 nasal swab).